arrow
J

Jaap Jan Boelens

Memorial Sloan Kettering Cancer Center
H指数:69
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Allogeneic haematopoietic stem cell transplantation in late-onset metachromatic leukodystrophy

异基因造血干细胞移植在迟发性异染性脑白质营养不良中的应用

Brain
IF11.7
2026-09-210
PRE
Therapeutic-drug-monitoring-based ATG Targeted Dosing Strategy in Unmanipulated Haploidentical Haematopoietic Stem Cell Transplantation: a randomized, multicenter, phase 3 clinical trial

基于治疗药物监测的ATG靶向给药策略在未处理的单倍型造血干细胞移植中的应用:一项随机、多中心、III期临床试验

2026-07-270
PRE
HLA-B*15:01 and HLA-DRB1*07:01 as novel markers of acute GVHD in pediatric HSCT

HLA-B*15:01和HLA-DRB1*07:01作为儿童HSCT中急性GVHD的新型标志物

2026-07-150
PRE
Gene Therapy for Sickle Cell Disease: Practice Recommendations from the American Society for Transplantation and Cellular Therapy and the International Society for Cell & Gene Therapy

镰状细胞病基因治疗:移植与细胞治疗学会和国际细胞与基因治疗学会的实践建议

2026-03-280
OAAI
Defibrotide for prophylaxis of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in pediatric high-risk patients: consensus guidelines from the European Society for Blood and Marrow Transplantation (EBMT)

Defibrotide用于儿童高危患者窦状阻塞综合征/静脉闭塞病(SOS/VOD)的预防:欧洲血液与骨髓移植学会(EBMT)的共识指南

2026-01-130
OAAI
Harmonized Immune Recovery Monitoring after HCT: Evidence & Practical Guidance from the Westhafen Intercontinental Group

异基因造血干细胞移植后免疫重建监测的标准化:Westhafen Intercontinental Group的证据与实践指南

2025-09-050
OAAI
Improved survival with model-based dosing of antithymocyte globulin in pediatric hematopoietic cell transplantation

模型指导的抗胸腺细胞球蛋白给药方案可提高儿科造血细胞移植的生存率

2025-02-210
OA
Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies

同种异体现货型CAR T细胞疗法用于复发或难治性B细胞恶性肿瘤

2025-02-051
OA
The role of the conditioning regimen for autologous and ex vivo genetically modified hematopoietic stem cell-based therapies: recommendations from the ISCT stem cell committee

预处理方案在自体和离体转基因造血干细胞治疗中的作用: 来自ISCT干细胞委员会的建议

2025-01-010
OAAI
Gene therapy in advanced metachromatic leukodystrophy: tempering expectations
2024-11-280
OAAI